Connecting via Winsock to STN

Welcome to STN International!  Enter x:x

* * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:36:08 ON 30 JUL 2008

=> file reg

=>
Uploading C:\Program Files\Stnexp\Queries\10522058.str





chain nodes :
17  18  19  20  21
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16
chain bonds :
11-19  12-20  15-17  15-21  16-18
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10  11-12  11-16  12-13  13-14
 14-15  15-16
exact/norm bonds :
1-2  1-6  2-3  3-4  4-5  11-12  11-16  11-19  12-13  12-20  13-14  14-15  15-16
15-17  15-21  16-18

normalized bonds :
5-6  5-7  6-10  7-8  8-9  9-10
isolated ring systems :
containing 1 : 11 :

G1:C,N

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:CLASS  18:CLASS  19:CLASS
20:CLASS  21:CLASS

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR







G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       114159 TO   123401
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

```
=> s l1 full

L3           18 SEA SSS FUL L1

=> d scan

L3   18 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   2-Cyclohexene-1-carboxamide, 4-[[(2,3-dihydro-1,4-dioxino[2,3-c]pyridin-7-
     yl)methyl]amino]-N-(5-fluoro-6-methoxy-4-quinolinyl)-1-hydroxy-,
     (1R,4S)-rel-
MF   C25 H25 F N4 O5

Relative stereochemistry.
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> file ca


=> s l3
L4           1 L3

=> d ibib abs fhitstr

L4   ANSWER 1 OF 1  CA  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         140:199210  CA
TITLE:                    Preparation of aminocyclohexene-substituted quinolines
                          and their azaisosteric analogues with antibacterial
                          activity
INVENTOR(S):              Davies, David Thomas; Elder, John Stephen; Forrest,
                          Andrew Keith; Jarvest, Richard Lewis; Pearson, Neil
                          David; Sheppard, Robert John
PATENT ASSIGNEE(S):       Glaxo Group Limited, UK
SOURCE:                   PCT Int. Appl., 60 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:
```

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004014361 | A1 | 20040219 | WO 2003-EP8153 | 20030723 |
| WO 2004014361 | A9 | 20040408 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2003251474 | A1 | 20040225 | AU 2003-251474 | 20030723 |
| EP 1539133 | A1 | 20050615 | EP 2003-784064 | 20030723 |
| EP 1539133 | B1 | 20060823 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| JP 2005538125 | T | 20051215 | JP 2004-526773 | 20030723 |
| AT 336995 | T | 20060915 | AT 2003-784064 | 20030723 |
| ES 2270142 | T3 | 20070401 | ES 2003-784064 | 20030723 |
| US 20060040925 | A1 | 20060223 | US 2005-522058 | 20050714 |
| PRIORITY APPLN. INFO.: | | | GB 2002-17294 A | 20020725 |
| | | | WO 2003-EP8153 W | 20030723 |
| OTHER SOURCE(S): | MARPAT 140:199210 | | | |

GI




I




II

AB Title compds. I [one of Z1-5 = N, one = CR1a and the remainder are CH, etc.; R1-1a = H, OH, (un)substituted alkoxy, etc.; R2 = H, (un)substituted-alkyl, -alkenyl; R3 = OH, alkoxy, alkenyloxy, etc.; R4 = alkyl, hydroxyalkyl, alkoxyalkyl, heterocycle, etc.; n = 0-1; AB = amido, carboxamido, acyl, etc.] and there pharmaceutically acceptable salts are prepd and disclosed as antibacterial agents. For instance, 4-amino-1-hydroxycyclohex-2-enecarboxylic acid N-(6-

methoxy[1,5]naphthyridin-4-yl)amide (preparation given) is reductively alkylated with 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxaldehyde to give II. II possessed an MIC of ≤ 2 μg/mL against S epidermidis CL7, S. aureus WCUH29, S. pneumoniae 1629, S. pyogenes CN10, H. influenzae ATCC 49247, E. faecalis 2, M. catarrhalis Ravasio, and E. coli 7623.

IT 661462-91-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminocyclohexene-substituted quinolines and their azaisosteric analogs with antibacterial activity)

RN 661462-91-5 CA

CN 2-Cyclohexene-1-carboxamide, 4-[[(3,4-dihydro-3-oxo-2H-pyrido[3,2-b]-1,4-thiazin-6-yl)methyl]amino]-1-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, (1R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



=> file marpat

=> s l1 full
FULL SEARCH INITIATED 11:37:06 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 38348 TO ITERATE

98.9% PROCESSED 37912 ITERATIONS 3 ANSWERS

100.0% PROCESSED 38348 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.24

L5 3 SEA SSS FUL L1

=> d ibib abs fqhit 1-3

L5 ANSWER 1 OF 3 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 146:100974 MARPAT
TITLE: Preparation of cyclitol glycosaminoglycan mimetics as antiviral agents
INVENTOR(S): Banwell, Martin Gerhardt; Bonnet, Muriel; Ferro, Vito; Kreipl, Andreas Th.; Renner, Jens; Offermann, Daniel Andrew
PATENT ASSIGNEE(S): Progen Industries Limited, Australia; The Australian National University

SOURCE: PCT Int. Appl., 105pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2006135973 | A1 | 20061228 | WO 2006-AU871 | 20060621 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: AU 2005-903280 20050622
GI



I



II



III

AB Cyclitol glycosaminoglycan mimetics I and II, wherein X is O, S, N, bond; Y is independently O, bond; R is H, CO2M, SO3M; wherein M is any pharmaceutically acceptable cation; both YR together, where Y is O, form a bridging acetal or ketal moiety bearing alkyl, aryl, arylalkyl; R1 is H, halo, CO2M, alkyl aryl; R2 is H, SO3M, CO2M, alkyl, aryl, arylalkyl, acyl; R3 is alkyl, aryl; R4 is H, alkyl, aryl; R3 and R4 are linked through a common alkyl, aryl, were prepared and tested in vitro as antiviral agents.

Thus, pyrrole cyclitol III was prepared as antiviral agent for the prevention or treatment in human of a disorder resulting from angiogenesis, metastasis, inflammation, coagulation, thrombosis, and/or microbial infection. Selected title compds. were tested against two types of herpes simplex virus HSV-1 and HSV-2 and as heparanase Inhibitor.

MSTR 1




G1 = 177




G6 = NH
G19 = OH
Patent location: claim 1
Note: additional ring formation also claimed
Note: substitution is restricted

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 3 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 140:199210 MARPAT
TITLE: Preparation of aminocyclohexene-substituted quinolines and their azaisosteric analogues with antibacterial activity
INVENTOR(S): Davies, David Thomas; Elder, John Stephen; Forrest, Andrew Keith; Jarvest, Richard Lewis; Pearson, Neil David; Sheppard, Robert John
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004014361 | A1 | 20040219 | WO 2003-EP8153 | 20030723 |
| WO 2004014361 | A9 | 20040408 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| AU 2003251474 | A1 | 20040225 | AU 2003-251474 | 20030723 | |
| EP 1539133 | A1 | 20050615 | EP 2003-784064 | 20030723 | |
| EP 1539133 | B1 | 20060823 | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | | |
| JP 2005538125 | T | 20051215 | JP 2004-526773 | 20030723 | |
| AT 336995 | T | 20060915 | AT 2003-784064 | 20030723 | |
| ES 2270142 | T3 | 20070401 | ES 2003-784064 | 20030723 | |
| US 20060040925 | A1 | 20060223 | US 2005-522058 | 20050714 | |
| PRIORITY APPLN. INFO.: | | | GB 2002-17294 | 20020725 | |
| | | | WO 2003-EP8153 | 20030723 | |

GI




I




II

AB Title compds. I [one of Z1-5 = N, one = CR1a and the remainder are CH, etc.; R1-1a = H, OH, (un)substituted alkoxy, etc.; R2 = H, (un)substituted-alkyl, -alkenyl; R3 = OH, alkoxy, alkenyloxy, etc.; R4 = alkyl, hydroxyalkyl, alkoxyalkyl, heterocycle, etc.; n = 0-1; AB = amido, carboxamido, acyl, etc.] and there pharmaceutically acceptable salts are prepd and disclosed as antibacterial agents. For instance, 4-amino-1-hydroxycyclohex-2-enecarboxylic acid N-(6-methoxy[1,5]naphthyridin-4-yl)amide (preparation given) is reductively alkylated with 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxaldehyde to give II. II possessed an MIC of ≤ 2 μg/mL against S epidermidis CL7, S. aureus WCUH29, S. pneumoniae 1629, S. pyogenes CN10, H. influenzae ATCC 49247, E. faecalis 2, M. catarrhalis

Ravasio, and E. coli 7623.

MSTR 1

G1 = 9



G2 = 177



G13 = 88

G15 = 182-1 183-176 / 184-1 185-176

G16 = bond
G19 = O
G24 = NH
G42 = 200



Patent location: claim 1
Note: also incorporates claims 13 and 14
Note: additional derivatization also claimed
Note: substitution is restricted

L5 ANSWER 3 OF 3 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 125:114325 MARPAT
TITLE: Aryloxycycloalkenyl and aryloxyiminocycloalkenylhydrox

yureas as 5-lipoxygenase inhibitors
INVENTOR(S): Kawai, Akiyoshi; Kawai, Makoto; Stevens, Rodney W.
PATENT ASSIGNEE(S): Pfizer Pharmaceuticals Inc., Japan; Pfizer Inc.
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9615106 | A1 | 19960523 | WO 1995-IB399 | 19950526 |
| W: CA, FI, JP, MX, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| CA 2205033 | A1 | 19960523 | CA 1995-2205033 | 19950526 |
| CA 2205033 | C | 20011211 | | |
| EP 790981 | A1 | 19970827 | EP 1995-918112 | 19950526 |
| EP 790981 | B1 | 19990908 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| AT 184272 | T | 19990915 | AT 1995-918112 | 19950526 |
| ES 2135066 | T3 | 19991016 | ES 1995-918112 | 19950526 |
| IN 1995DE01959 | A | 20050311 | IN 1995-DE1959 | 19951025 |
| IL 115853 | A | 19990817 | IL 1995-115853 | 19951102 |
| NO 9504530 | A | 19960513 | NO 1995-4530 | 19951109 |
| AU 9537764 | A | 19960516 | AU 1995-37764 | 19951109 |
| AU 690354 | B2 | 19980423 | | |
| ZA 9509512 | A | 19970509 | ZA 1995-9512 | 19951109 |
| BR 9505130 | A | 19970909 | BR 1995-5130 | 19951109 |
| CZ 282832 | B6 | 19971015 | CZ 1995-2942 | 19951109 |
| RU 2119479 | C1 | 19980927 | RU 1995-119414 | 19951109 |
| KR 182321 | B1 | 19990515 | KR 1995-40425 | 19951109 |
| PL 179023 | B1 | 20000731 | PL 1995-311325 | 19951109 |
| FI 9701994 | A | 19970509 | FI 1997-1994 | 19970509 |
| FI 113643 | B1 | 20040531 | | |
| GR 3031378 | T3 | 20000131 | GR 1999-402472 | 19990929 |
| PRIORITY APPLN. INFO.: | | | WO 1994-JP1897 | 19941110 |
| | | | WO 1995-IB399 | 19950526 |

OTHER SOURCE(S): CASREACT 125:114325
GI




I

AB The present invention provides preparation of title compds. I [Ar = Ph, naphthyl, biphenyl, each optionally substituted with C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C2-4 alkoxyalkoxy, C1-4 alkylthio, hydroxy, halo, cyano, amino, C1-4 alkylamino, di(C2-8)alkylamino, C2-6 alkanoylamino, carboxy, C2-6

alkoxycarbonyl, or optionally substituted Ph, phenoxy, phenylthio or phenylsulfinyl; furyl, benzo[b]furyl, thienyl, benzo[b]thienyl, pyridyl, quinolyl, each optionally substituted with C1-4 alkyl, C1-4 haloalkyl, halo, C1-4 alkoxy, optionally-substituted Ph, phenoxy or phenylthio, X = C1-C4 alkylene, C2-C4 alkenylene, -(CHR1)m-Q1-(CHR2)n-, -O-(CHR1)jQ2- and -(CHR1)-O-N; N moiety is attached to the cycloalkene ring; Q1 = O, S, SO, SO2, NR3, CH:N-O, CO; Q2 = O, S, SO, SO2, NR3; R1, R2, R3 = H, C1-C4 alkyl; m, n = 0-4; j = 1-4; p = 1, 2; Y = H, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C2-4 alkoxyalkyl, C1-4 alkylthio, hydroxy, halo, cyano, amino; Z = H, C1-4 alkyl; M = H, a pharmaceutically acceptable cation or a pharmaceutically acceptable metabolically cleavable group]. Further the invention provides a pharmaceutical composition for treating a medical condition for which a 5-lipoxygenase inhibitor is needed in a mammalian subject which comprises a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. Preferably the medical condition is an inflammatory disease, allergy or cardiovascular diseases. Thus, deprotection of N,O-bis(tert-butoxycarbonyl)-N-{(1R,4R)-trans-4-(4-fluorophenoxy)-2-cyclopentyl-1-yl}hydroxylamine (preparation given) with TFA gave hydroxylamine which on treatment with Me3SiNCO in THF gave title compound, N-{(1R,4R)-trans-4-(4-fluorophenoxy)-2-cyclopenten-1-yl}-N-hydroxyurea.

MSTR 1




G1 = quinolinyl (opt. substd.)
G8 = 10-1 11-3


G9 = 38-10 41-3




G12 = 120-1 121-11


G16 = O
Patent location: claim 1

Note:                          substitution is restricted

=> d his

     (FILE 'HOME' ENTERED AT 11:36:08 ON 30 JUL 2008)

     FILE 'REGISTRY' ENTERED AT 11:36:22 ON 30 JUL 2008
L1                STRUCTURE UPLOADED
L2              0 S L1 SAM
L3             18 S L1 FULL

     FILE 'CA' ENTERED AT 11:36:48 ON 30 JUL 2008
L4              1 S L3

     FILE 'MARPAT' ENTERED AT 11:37:03 ON 30 JUL 2008
L5              3 S L1 FULL

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 11:37:53 ON 30 JUL 2008